Biolife Solutions Inc BLFS
We take great care to ensure that the data presented and summarized in this overview for BIOLIFE SOLUTIONS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BLFS
View all-
Casdin Capital, LLC New York, NY8.71MShares$191 Million19.45% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$120 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA3.24MShares$71 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.84MShares$62.1 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY1.59MShares$34.9 Million0.21% of portfolio
-
State Street Corp Boston, MA1.47MShares$32.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.15MShares$25.1 Million0.02% of portfolio
-
William Blair Investment Management, LLC Chicago, IL910KShares$19.9 Million0.06% of portfolio
-
Cramer Rosenthal Mcglynn LLC Greenwich, CT906KShares$19.8 Million1.39% of portfolio
-
Dimensional Fund Advisors LP Austin, TX887KShares$19.4 Million0.01% of portfolio
Latest Institutional Activity in BLFS
Top Purchases
Top Sells
About BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
Insider Transactions at BLFS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 09
2025
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
932
-0.49%
|
$18,640
$20.11 P/Share
|
|
Apr 09
2025
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
286
-0.15%
|
$5,720
$20.11 P/Share
|
|
Apr 09
2025
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
324
-0.24%
|
$6,480
$20.11 P/Share
|
|
Apr 09
2025
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
210
-0.26%
|
$4,200
$20.11 P/Share
|
|
Apr 09
2025
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
569
-0.18%
|
$11,380
$20.11 P/Share
|
|
Apr 07
2025
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
27,994
+0.32%
|
-
|
|
Apr 01
2025
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,589
-3.31%
|
$232,958
$22.66 P/Share
|
|
Apr 01
2025
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
7,869
-3.86%
|
$173,118
$22.66 P/Share
|
|
Apr 01
2025
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,687
-11.95%
|
$565,114
$22.66 P/Share
|
|
Apr 01
2025
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
8,902
-6.15%
|
$195,844
$22.66 P/Share
|
|
Apr 01
2025
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
5,771
-6.72%
|
$126,962
$22.66 P/Share
|
|
Mar 18
2025
|
Sarah Aebersold Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,068
+19.75%
|
-
|
|
Mar 18
2025
|
Roderick De Greef President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
112,835
+17.61%
|
-
|
|
Mar 18
2025
|
Sean Werner Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,919
+45.2%
|
-
|
|
Mar 18
2025
|
Joydeep Goswami Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,876
+12.53%
|
-
|
|
Mar 18
2025
|
Troy Wichterman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,120
+20.78%
|
-
|
|
Mar 18
2025
|
Todd Berard Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,897
+12.95%
|
-
|
|
Mar 18
2025
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,564
+8.87%
|
-
|
|
Mar 18
2025
|
Rachel Ellingson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,876
+12.13%
|
-
|
|
Mar 18
2025
|
Karen A. Foster Chief Quality and Operations |
BUY
Grant, award, or other acquisition
|
Direct |
48,810
+11.31%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 459K shares |
|---|---|
| Exercise of conversion of derivative security | 50K shares |
| Other acquisition or disposition | 178K shares |
| Open market or private sale | 286K shares |
|---|---|
| Other acquisition or disposition | 150K shares |